Loading clinical trials...
Loading clinical trials...
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
3176154559clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
NCT07233148 · Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), and more
NCT07369076 · Amyotrophic Lateral Sclerosis (ALS)
NCT07660614 · Amyotrophic Lateral Sclerosis
NCT03489278 · Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, and more
NCT07295990 · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
UZ Leuven
Leuven
McGill University Health Centre
Montreal
Sunnybrook Research Institute
Toronto
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions